Article

Aton acquires U.S. marketing rights for timolol

Aton Pharma Inc. has acquired the U.S. marketing rights to the timolol (Timoptic) product line from Merck & Co. Inc.

Lawrenceville, NJ

-Aton Pharma Inc. has acquired the U.S. marketing rights to the timolol (Timoptic) product line from Merck & Co. Inc.

This acquisition includes rights to:
• Timolol maleate (Timoptic Ophthalmic Solution).
• Timolol maleate ophthalmic solution in a sterile ophthalmic unit dose dispenser (Timoptic in Ocudose)-the only preservative-free medication for glaucoma available in the United States, according to Aton Pharma.
• Timolol maleate ophthalmic gel-forming solution (Timoptic-XE Ophthalmic). Timolol is a nonselective, beta-adrenergic receptor blocker indicated for the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Aton Pharma also provides a hydroxypropyl cellulose ophthalmic insert (Lacrisert), a preservative-free, once-daily, sustained-release prescription insert for moderate to severe dry eye.

“Aton Pharma has made the strategic decision to expand our commitment within the field of ophthalmology,” said Michael G. Wells, chief executive officer of Aton Pharma. “The acquisition of the [timolol] franchise significantly enhances our profile within the ophthalmology community while enabling us to serve yet another niche market that is greatly underserved.”

According to market research done by Aton Pharma, more than 60% of ophthalmologists are not aware that preservative-free preparations of timolol are available. In addition, the company said its research indicated that more than 80% of ophthalmologists are particularly concerned about the use of glaucoma medications containing preservatives in patients with compromised ocular surfaces.

“A large body of evidence has indicated that ocular preservatives, particularly benzalkonium chloride, impair surface tissues of the eye, leading to inflammation, dry eye, and other issues,” said Penny Asbell, MD, professor of ophthalmology, Mount Sinai School of Medicine, New York.

“This is particularly problematic in glaucoma patients, who must use medication frequently and for long periods of time,” she added. “Preservative-free product options are important for these patients with dry eyes.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.